Other Financings Of Public Biotechnology Companies: January 2006
Total: $386.5M | ||||
Company | Type Of | Number Of | Amount | Investors; Placement Agents; Details |
Akesis | Private placement of stock and warrants | 2S and 1W | $4 | The shares are being sold at $2 each; the three- year warrants are exercisable at $3 per share (1/6) |
Amarin Corp. | Private placement of stock and warrants | 0.8S and 0.28W | $2 | The shares were sold at $2.50 each to existing investor Tony Ryan; the warrants are exercisable at $3.06 per share (1/23) |
Biomira Inc. | Private placement of stock and warrants | 10.572S and 2.643W | $16.1 | Units consisting of one share and 25% of a warrant were sold at $1.52 apiece; each whole warrant is exercisable for 42 months at $1.52 per share; Rodman & Renshaw LLC was placement agent (1/27) |
Biopure Corp. | Sale of stock and warrants | 4.11S and 4.11W | $3.37 | The shares were sold at $3.37 each; the warrants are exercisable at $1.025 each; Dawson James Securities Inc. and Noble International Investments Inc. were underwriters (1/17) |
Corgenix | Private placement of convertible stock, notes and warrants | N/A and 18.8W | $3.36 | In one deal Barron Partners LP bought $2M in pre- ferred stock, convertible into about 5.7M common shares; it also got 15M warrants exercisable from $0.40 to $0.60 per share; in a second deal investors bought $1.36M in convertible notes; they got 3.8M warrants exercisable at $0.23 per share; Ascendiant Securities LLC was placement agent for the deals (1/3) |
Cytokinetics | Registered direct offering | 5.5S | $33 | Federated Kaufmann and Red Abbey Venture Partners purchased the shares at $6.60 each; Pacific Growth Equities LLC was adviser in the deal (1/18) |
DOR | Stock purchase agreement | N/A | $6 | Fusion Capital Fund II LLC agreed to purchase up to $400,000 of DOR stock at the market price each month for 15 months; DOR will control the timing and amount of stock sold (1/19) |
GammaCan | Private placement of securities | 1.6S and | $1.2 | The stock and warrants were placed privately in two separate deals (1/17) |
Genmab A/S | Private placement of stock | 5.75S | DKK845.2 ($136) | The shares were sold to institutional investors; underwriters were Merrill Lynch & Co., ABN AMRO Rothschild, and Alfred Berg SE (1/27) |
GW | Private placement of stock and warrants | 6.166S and 1.85W | £8.6 ($15) | The shares were placed with a U.S.-based institutional investor at 139.6 pence each; half of the five-year warrants are exercisable at £1.61 per share and half at £1.745 per share; Seven Hills Partners LLC was placement agent (1/4) |
Intercytex | Private placement of stock | 13.89S | £15 ($26.4) | The company gained a listing on the AIM through the deal, in which existing investors purchased £4.2M of stock, and new investors bought £10.8M worth, all at 108 pence per share; Piper Jaffray Ltd. was the deal's nominated adviser and broker (1/27) |
Lipoxen plc | Private placement of stock | 28S | £3.8 ($6.7) | Shares were priced at 13.5 pence each in the deal; Canaccord Adams Ltd. was broker and Grant Thornton Corporate Finance was nominated adviser (1/17) |
Matritech Inc. | Private placement of convertible notes and warrants | N/A and 7.5W | $7 | The 15% notes are due in January 2009 and are convertible in 10.77M shares; five-year warrants in the deal are convertible into 6.46M shares at $0.67 per share, and the placement agents got warrants to buy 1.04M shares at $0.65 per share; investors included SDS Capital Partners and H&Q Life Science Investors (1/17) |
Medicure Inc. | Bought-deal financing | 7.75S | C$12 ($10.3) | Underwriters led by Blackmont Capital Inc. and including National Bank Financial Inc. purchased the shares at C$1.55 each; totals include 1.25M shares bought via their overallotment option (1/4) |
NanoLogix | Investment | ND | $0.75 | The Nutmeg Group provided a financing commitment of $0.75M; terms were not disclosed (1/12) |
NexMed Inc. | Private placement of stock and warrants | 9.347S and 3.739W | $8.32 | The shares were sold at $0.89 each; the four-year warrants are exercisable at $1.11 per share; investors included Southpoint Capital Advisors LP and Loeb Partners Corp. (1/25) |
NitroMed Inc. | Registered direct offering | 6.1S | $62.5 | The shares were sold from a shelf registration at $10.25 each; JP Morgan Securities Inc. and Thomas Weisel Partners LLC were placement agents (1/25) |
Pharming | Private placement of stock and warrants | 4.5S and 0.675W | €17.1 ($20.5) | The shares were sold at €3.80 each, and the two- year warrants are exercisable at €4 per share; Amsterdams Effectenkantoor, Fortis Bank and Rabo Securities were placement agents (1/25) |
Procyon | Private placement of special warrants and units | 78.6SW | C$18.1 ($15.7) | The special warrants, priced at C$0.23 each, entitle the holder to one common share and a five- year warrant to purchase one share at C$0.35; lead agent Dundee Securities Corp. was joined by Loewen, Ondaatje, McCutcheon Ltd. and Desjardins Securities Inc. in the deal (1/19) |
Provectus | Private placement of equity | ND | $8.3 | Network 1 Financial Securities Inc. and Chicago Investment Group were placement agents for the deal, terms of which were not disclosed (1/5) |
Notes: | ||||
This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TSE = Toronto Stock Exchange. | ||||